| Typicality: | 0.317 |
| Saliency: | 0.159 |
| as immunostimulatory agents | 6 | manner |
| further | 2 | manner |
| invention → provide → oligonucleotide | 4 |
| invention → relate to → therapeutic use of oligonucleotides | 3 |
| invention → relate to → oligonucleotide | 3 |
| negative | neutral | positive |
| 0.032 | 0.772 | 0.197 |
| Raw frequency | 10 |
| Normalized frequency | 0.159 |
| Modifier score | 0.500 |
| Perplexity | 61.718 |